Daratumumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Daratumumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
361
Registered trials
592
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Daratumumab can convert its Monoclonal antibody profile and CD38 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Daratumumab (query alias: daratumumab) |
|---|---|
| Modality / target | Monoclonal antibody; CD38; CD38 inhibitors, ADCC, Antibody-dependent cellular phagocytosis (ADCP) effects |
| Highest global status | Approved |
| Originator | Janssen Global Services LLC |
| Active developers | Janssen LP, Xian-Janssen Pharmaceutical Ltd., Janssen Pharmaceuticals, Inc. |
The MCP disease footprint includes Smoldering Multiple Myeloma, Immunoglobulin Light-Chain Amyloidosis, Refractory Multiple Myeloma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07649525 | Phase 3 | Recruiting | 1226 | iFIT1: Progression-free survival (PFS) |
| NCT07665450 | Phase 3 | Not yet recruiting | 1000 | Progression-Free Survival (PFS) |
| NCT07671287 | Phase 3 | Not yet recruiting | 399 | To determine the efficacy (MRD negativity at a level of 10-6) of Tec-DRd compared to DVRd after induction/consolidation therapy and HD melphalan and ASCT, before start of maintenance therapy in participants with TE NDMM |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
SAFETY AND EFFICACY OF DARATUMUMAB IN TREATMENT-REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE LONG-TERM EXTENSION OF A PHASE 2 TRIAL
Phase 2; n=10; evaluation: Positive. Reported fields: AE = the most common adverse events included hypogammaglobulinemia, infections and gastrointestinal symptoms.
EARLY CLINICAL AND SEROLOGICAL EFFECTS OF ABATACEPT-DARATUMUMAB COMBINATION THERAPY IN INDIVIDUALS WITH ACTIVE AND ACPA-POSITIVE RHEUMATOID ARTHRITIS: PHASE I RESULTS OF THE CURACTA TRIAL
Phase 1/2; n=3; evaluation: Positive. Reported fields: AE = Most AEs were mild or moderate. All patients experienced transient non-severe symptoms indicative of systemic infusion-related reactions (IRR; e.g. erythema, hyperhidrosis), and one patient experienced local IRR. One patient had transient grade 4 neutropenia with leukopenia, which resolved without intervention. Total IgG levels decreased in all patients, and one patient received immunoglobulin replacement therapy due to IgG levels below 4g/l (week 24). No severe infections occurred.
ASSESSMENT OF THE USE OF BIOLOGIC DRUGS IN THE TREATMENT OF PRIMARY ANTIPHOSPHOLIPID ANTIBODY SYNDROME
Not Applicable; n=100; evaluation: Positive. Reported fields: clinical improvement(complement-mediated APS presentations) = 60.0 % ; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Daratumumab addresses Smoldering Multiple Myeloma, Immunoglobulin Light-Chain Amyloidosis, Refractory Multiple Myeloma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2012-08-30 | Genmab Enters Worldwide Agreement with Janssen for Daratumumab | Phase 1/2 | US$55.0M upfront; US$1,000.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Methods for treating multiple myeloma comprising an Anti-CD38 antibody combined with bortezomib, lenalidomide and dexamethasone”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
